Catalent Inc (CTLT) FinancialsCTLTCatalent Inc

Catalent Inc (CTLT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Manufacturing & commercial product supply, accounting for 59.2% of total sales, equivalent to $606.00M. Another important revenue stream is Development services. Understanding this composition is critical for investors evaluating how CTLT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Catalent Inc maintains a gross margin of 17.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.39%, while the net margin is -12.61%. These profitability ratios, combined with a Return on Equity (ROE) of -11.19%, provide a clear picture of how effectively CTLT converts its operational activities into shareholder value.

In the context of the broader market, CTLT competes directly with industry leaders such as SRPT and INSM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CTLT's gross margin of 17.69% stands against SRPT's 62.59% and INSM's 83.71%. Such benchmarking helps identify whether Catalent Inc is trading at a premium or discount relative to its financial performance.